[HTML][HTML] Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe
T Hofmarcher, P Lindgren, N Wilking - Journal of Cancer Policy, 2022 - Elsevier
Background Systemic anti-cancer therapy (SACT) is the recommended treatment modality in
patients with advanced non-small cell lung cancer (aNSCLC) in clinical guidelines. SACT …
patients with advanced non-small cell lung cancer (aNSCLC) in clinical guidelines. SACT …
[HTML][HTML] Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
JS Ju, ACC Huang, PH Tung, CH Huang, TH Chiu… - Scientific Reports, 2023 - nature.com
Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …
LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab
Y Wu, B Du, C Lv, X Ji, J Lai - Annals of Medicine, 2023 - Taylor & Francis
Background To establish a risk stratification score to facilitate individualized treatment for
patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
M Galvez‐Nino, R Ruiz, K Roque, O Coanqui… - Thoracic …, 2023 - Wiley Online Library
Background Despite the advances in the management of advanced non–small cell lung
cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in …
cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in …
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma
H Lu, B Zhang, Y Xie, W Zhao, W Han, L Zhou… - Investigational New …, 2023 - Springer
Glioblastoma (GBM) is a highly lethal neurological tumor that presents significant challenge
for clinicians due to its heterogeneity and high mortality rate. Despite extensive research …
for clinicians due to its heterogeneity and high mortality rate. Despite extensive research …
[HTML][HTML] Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World …
G Corrao, M Franchi, M Zaffaroni, MG Vincini… - Cancers, 2023 - mdpi.com
Simple Summary This study aims to compare effectiveness and cost profile in non-small-cell
lung cancer (NSCLC) patients harboring synchronous brain metastases (BMs) who received …
lung cancer (NSCLC) patients harboring synchronous brain metastases (BMs) who received …
[HTML][HTML] Refusal of subsequent treatment in patients with EGFR-mutant non-small-cell lung cancer after response to EGFR-TKIs
S Hashimoto, Y Fujii, M Ujiie, K Miyazaki… - Cancer Diagnosis & …, 2023 - ncbi.nlm.nih.gov
Background/Aim: During the course of effective and long-term treatment with epidermal
growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), some elderly patients might …
growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), some elderly patients might …
Epidermal growth factor receptor mutation p. A864V in small cell lung cancer and lung squamous cell carcinoma: a case report and review of literature
W Deng, G Chen, D Xiong, R He, K Wang, H Lu… - Anti-Cancer …, 2022 - journals.lww.com
Mutations in the epidermal growth factor receptor (EGFR) have been identified in 10–20% of
nonsmall cell lung cancer (NSCLC), specifically lung adenocarcinomas. However, these …
nonsmall cell lung cancer (NSCLC), specifically lung adenocarcinomas. However, these …